The call ran from 11:01 AM to 12:30 PM IST (1 h 29 min).
Key takeaways
Q2 revenue ₹988 Cr (+16.2%) and PAT ₹85 Cr (+16.1%) are real but base-aided. Q2 EBITDA margin fell to 21.1% from 22.1%, and management leans on 2028-30 launches.
| Management target | Net Profit 50.0% FY27 |
|---|
| Revenue growth | Q2 +16.2% YoY, +4.4% QoQ; H1 +17.8%. |
|---|---|
| Margins | Q2 EBITDA margin 21.1% vs 22.1% YoY; H1 up to 21.3%. |
| Demand visibility | API H2 visibility strong; animal health guided 20%+ growth. |
| Management confidence | Upbeat; 'strong' repeated, hedged on US and human health. |
Growth
Q2 revenue +16.2% YoY and +4.4% QoQ; H1 +17.8%. US sales fell YoY against a one-off exclusivity quarter last year.
Outlook
Guides PAT growth above 50% in FY27 (H1 +49%). Capex ~₹150 Cr over two years. ₹20 Cr loan prepayment considered; Europe launch next year.
Risks
Q2 gross margin 53.7% vs 55.5%. Q2 ESOP cost ~₹42 Cr, with ~₹40 Cr/quarter expected. Human health launches delayed; 2029-30 pipeline unproven.
Last quarter's promises, checked
Delivered
- Rev growth 13-15% → H1 +17.8% (= BEAT)
- API growth 13-14% → Q2 API ~20% (= BEAT)
- BFL close in 2-3 mths → acquired (= BEAT)
Partly delivered
- EBITDA margin 20-22% → Q2 21.1%, down from 22.1% (= PARTIAL)
- Animal Health 20%+ → companion ~60%; total n/a (= PARTIAL)
Missed
- Capex ₹250-300Cr/yr → ~₹150Cr over 2 yrs (= MISS)
- Q2 ESOP ₹40Cr → ₹42Cr (= MISS)
- 1-2 Human launches FY27 → delayed (= MISS)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
The results behind this call
Viyash Scientific Q2 FY27 Results: Net Profit ₹84.7 Cr, Up 16.2% YoY
Viyash Scientific Ltd filed unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Standalone revenue from operations was INR 3,906.50 million for the quarter.
- Key figure
- Net profit ₹84.7 Cr · +16.2% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Targeting $1 billion revenue by FY32 with 18% CAGR; focused on companion animal and complex oncology APIs.
Growth they described
Revenue grew 19.5% YoY to ₹946 Cr; EBITDA increased 59.2% led by operational efficiency and backward integration.
Call details
| Company | Viyash Scientific Ltd |
|---|---|
| NSE symbol | VIYASH |
| ISIN | INE807F01027 |
| Call | Q2 FY27 earnings call |
| Date | Saturday, 14 November 2026 |
| Time | 11:00 AM IST |
| Length | 1 h 29 min |
| Audio | Our stream on YouTube ↗ |
Viyash Scientific Ltd: key numbers
- Share price
- ₹233.36
- Market cap
- ₹10,314 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 44.4×Sector 49.0×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.